Glucagon-like peptide-1 receptor agonists favorably address all components of metabolic syndrome

World Journal of Diabetes

Volumn 7, Issue 18, 2016, Pages 441-448

  Chatterjee, Sanjay ^a   Ghosal, Samit ^b   Chatterjee, Saurav ^c  

^a Apollo Gleneagles Hospital   (India)

^b Nightingale Hospital   (India)

^c ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

Body weight; Diabetes; Glucagonlike peptide 1 receptor agonists; Lipids; Metabolic syndrome; Microalbuminuria

Indexed keywords

ALBIGLUTIDE; DULAGLUTIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; LIPID; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; SEMAGLUTIDE;

ACUTE CORONARY SYNDROME; ANTIDIABETIC ACTIVITY; CARDIAC MUSCLE CELL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DYSLIPIDEMIA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INCIDENCE; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; METABOLIC PARAMETERS; METABOLIC SYNDROME X; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OUTCOME ASSESSMENT; SHORT SURVEY; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; VASCULAR ENDOTHELIUM; WEIGHT REDUCTION;

EID: 85010310748     PISSN: None     EISSN: 19489358     Source Type: Journal    
DOI: 10.4239/wjd.v7.i18.441     Document Type: Short Survey

References (45)

1. Haller H. [Epidermiology and associated risk factors of hyperlipoproteinemia]. Z Gesamte Inn Med 1977; 32: 124-128 [PMID: 883354]
2. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607 [PMID: 3056758 DOI: 10.2337/diabetes.37.12.1595]
3. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359 [PMID: 11790215 DOI: 10.1001/jama.287.3.356]
4. Hanley AJ, Williams K, Festa A, Wagenknecht LE, D'Agostino RB, Haffner SM. Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes 2005; 54: 3140-3147 [PMID: 16249437 DOI: 10.2337/diabetes.54.11.3140]
5. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645 [PMID: 19805654 DOI: 10.1161/CIRCULATIONAHA.109.192644]
6. Beltr�n-S�nchez H, Harhay MO, Harhay MM, McElligott S. Prevalence and trends of metabolic syndrome in the adult U.S. population, 1999-2010. J Am Coll Cardiol 2013; 62: 697-703 [PMID: 23810877 DOI: 10.1016/j.jacc.2013.05.064]
7. Survey Methods and Analytic Guidelines. Available from: URL: http://www.cdc.gov/nchs/nhanes/survey_methods.htm
8. Brunton S. GLP-1 receptor agonists vs. DPP-4 inhibitors for type diabetes: is one approach more successful or preferable than the other? Int J Clin Pract 2014; 68: 557-567 [PMID: 24499291 DOI: 10.1111/ijcp.12361].
9. Emisphere's SNAC Carrier Achieves Provisional GRAS Status for Use with Nutrients Added to Foods and Dietary Supplements. [accessed 2016 Apr 26]. Available from: URL: http://ir.emisphere. com/releasedetail.cfm?releaseid=381129
10. Venkat MV, Regier EE, Close KL. American Diabetes Association 74th Annual Scientific Sessions (ADA 2014). J Diabetes 2014; 6: 491-495 [DOI: 10.1111/1753-0407.12219]
11. Rosenstock J, Diamant M, Silvestre L, Souhami E, Zhou T, Fonseca V. Benefits of a fixed-ratio formulation of once-daily insulin glargine/lixisenatide (LixiLan) vs glargine in type 2 diabetes (T2DM) Inadequately Controlled on Metformin. Diabetes 2014; 63 Suppl 1: A1-A102 [DOI: 10.2337/db14-1-388]
12. Fineman MS, Cirincione BB, Maggs D, Diamant M. GLP-1 based therapies: differential effects on fasting and postprandial glucose. Diabetes Obes Metab 2012; 14: 675-688 [PMID: 22233527 DOI: 10.1111/j.1463-1326.2012.01560.x]
13. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 1092-1100 [PMID: 15855572 DOI: 10.2337/diacare.28.5.1092]
14. Blevins T, Pullman J, Malloy J, Yan P, Taylor K, Schulteis C, Trautmann M, Porter L. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 2011; 96: 1301-1310 [PMID: 21307137 DOI: 10.1210/jc.2010-2081]
15. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallelgroup, multinational, open-label trial (LEAD-6). Lancet 2009; 374: 39-47 [PMID: 19515413 DOI: 10.1016/S0140-6736(09)60659-0]
16. Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, Zdravkovic M, Ravn GM, Sim� R. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009; 52: 2046-2055 [PMID: 19688338 DOI: 10.1007/s00125-009-1472-y]
17. Pratley RE, Nauck MA, Barnett AH, Feinglos MN, Ovalle F, Harman-Boehm I, Ye J, Scott R, Johnson S, Stewart M, Rosenstock J. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol 2014; 2: 289-297 [PMID: 24703047 DOI: 10.1016/S2213-8587(13)70214-6]
18. Wysham C, Blevins T, Arakaki R, Colon G, Garcia P, Atisso C, Kuhstoss D, Lakshmanan M. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care 2014; 37: 2159-2167 [PMID: 24879836 DOI: 10.2337/dc13-2760].
19. Novo Nordisk successfully completes first phase 3a trial with semaglutide in people with type 2 diabetes. [accessed 2016 Feb 5]. Available from: URL: https://www.novonordisk.com/bin/getPDF. 1934243.pdf
20. Wang B, Zhong J, Lin H, Zhao Z, Yan Z, He H, Ni Y, Liu D, Zhu Z. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Diabetes Obes Metab 2013; 15: 737-749 [PMID: 23433305 DOI: 10.1111/dom.12085]
21. Voukali M, Kastrinelli I, Stragalinou S, Tasiopoulou D, Paraskevopoulou P, Katsilambros N, Kokkinos A, Tentolouris N, Ioannidis I. Study of postprandial lipaemia in type 2 diabetes mellitus: exenatide versus liraglutide. J Diabetes Res 2014; 2014: 304032 [PMID: 25165723 DOI: 10.1155/2014/304032]
22. Rizzo M, Chandalia M, Patti AM, Di Bartolo V, Rizvi AA, Montalto G, Abate N. Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study. Cardiovasc Diabetol 2014; 13: 49 [PMID: 24559258 DOI: 10.1186/1475-2840-13-49]
23. Zhang H, Zhang X, Hu C, Lu W. Exenatide reduces urinary transforming growth factor-β1 and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria. Kidney Blood Press Res 2012; 35: 483-488 [PMID: 22687869 DOI: 10.1159/000337929]
24. Kodera R, Shikata K, Kataoka HU, Takatsuka T, Miyamoto S, Sasaki M, Kajitani N, Nishishita S, Sarai K, Hirota D, Sato C, Ogawa D, Makino H. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 2011; 54: 965-978 [PMID: 21253697 DOI: 10.1007/s00125-010-2028-x]
25. Ghosal S. Using liraglutide in combination with insulin therapy for type 2 diabetic patients: An early clinical experience data. Diabetes 2011; 60 Suppl 1: A235-A352 [DOI: 10.2337/db11-868-1281]
26. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012; 8: 728-742 [PMID: 22945360 DOI: 10.1038/nrendo.2012.140]
27. Min DK, Tuor UI, Koopmans HS, Chelikani PK. Changes in differential functional magnetic resonance signals in the rodent brain elicited by mixed-nutrient or protein-enriched meals. Gastroenterology 2011; 141: 1832-1841 [PMID: 21802388 DOI: 10.1053/j.gastro.2011.07.034]
28. Schl�gl H, Kabisch S, Horstmann A, Lohmann G, M�ller K, Lepsien J, Busse-Voigt F, Kratzsch J, Pleger B, Villringer A, Stumvoll M. Exenatide-induced reduction in energy intake is associated with increase in hypothalamic connectivity. Diabetes Care 2013; 36: 1933-1940 [PMID: 23462665 DOI: 10.2337/dc12-1925]
29. Jensterle Sever M, Kocjan T, Pfeifer M, Kravos NA, Janez A. Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin. Eur J Endocrinol 2014; 170: 451-459 [PMID: 24362411 DOI: 10.1530/EJE-13-0797]
30. Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skj�th TV, Andreasen AH, Jensen CB, DeFronzo RA. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA 2015; 314: 687-699 [PMID: 26284720 DOI: 10.1001/jama.2015.9676]
31. Wu H, Sui C, Xu H, Xia F, Zhai H, Zhang H, Weng P, Han B, Du S, Lu Y. The GLP-1 analogue exenatide improves hepatic and muscle insulin sensitivity in diabetic rats: tracer studies in the basal state and during hyperinsulinemic-euglycemic clamp. J Diabetes Res 2014; 2014: 524517 [PMID: 25580440 DOI: 10.1155/2014/524517]
32. Tarantino G, Finelli C. What about non-alcoholic fatty liver disease as a new criterion to define metabolic syndrome? World J Gastroenterol 2013; 19: 3375-3384 [PMID: 23801829 DOI: 10.3748/wjg.v19.i22.3375]
33. Lonardo A, Ballestri S, Marchesini G, Angulo P, Loria P. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Dig Liver Dis 2015; 47: 181-190 [PMID: 25739820 DOI: 10.1016/j.dld.2014.09.020]
34. Ohki T, Isogawa A, Iwamoto M, Ohsugi M, Yoshida H, Toda N, Tagawa K, Omata M, Koike K. The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone. ScientificWorldJournal 2012; 2012: 496453 [PMID: 22927782 DOI: 10.1100/2012/496453]
35. Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, Hazlehurst JM, Guo K, Abouda G, Aldersley MA, Stocken D, Gough SC, Tomlinson JW, Brown RM, H�bscher SG, Newsome PN. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 2016; 387: 679-690 [PMID: 26608256 DOI: 10.1016/S0140-6736(15)00803-X]
36. Woo JS, Kim W, Ha SJ, Kim JB, Kim SJ, Kim WS, Seon HJ, Kim KS. Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study. Arterioscler Thromb Vasc Biol 2013; 33: 2252-2260 [PMID: 23868944 DOI: 10.1161/ATVBAHA.113.301586]
37. Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2014; 16: 38-47 [PMID: 23829656 DOI: 10.1111/dom.12175]
38. Sj�holm A. Impact of glucagon-like peptide-1 on endothelial function. Diabetes Obes Metab 2009; 11 Suppl 3: 19-25 [PMID: 19878258 DOI: 10.1111/j.1463-1326.2009.01074.x]
39. Deacon CF. Potential of liraglutide in the treatment of patients with type 2 diabetes. Vasc Health Risk Manag 2009; 5: 199-211 [PMID: 19436648 DOI: 10.2147/VHRM.S4039]
40. Victoza� Significantly Reduced the Risk of Major Adverse Cardiovascular Events in the LEADER Trial. [accessed 2016 May 11]. Available from: URL: http://www.prnewswire.com/newsreleases/victoza-significantly-reduced-the-risk-of-major-adversecardiovascular-events-in-the-leader-trial-300231181.html
41. Semaglutide significantly reduces the risk of major adverse cardiovascular events in the SUSTAIN 6 trial. [accessed 2016 May 9]. Available from: URL: https://globenewswire.com/newsrelease/2016/04/28/834013/0/en/Semaglutide-significantlyreduces-the-risk-of-major-adverse-cardiovascular-events-in-the-SUSTAIN-6-trial.html
42. Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM, Zhou YQ, Riazi AM, Baggio LL, Henkelman RM, Husain M, Drucker DJ. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009; 58: 975-983 [PMID: 19151200 DOI: 10.2337/db08-1193]
43. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, K�ber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJ, Probstfield JL, Riddle MC, Solomon SD, Tardif JC. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med 2015; 373: 2247-2257 [PMID: 26630143 DOI: 10.1056/NEJMoa1509225]
44. Marso SP, Poulter NR, Nissen SE, Nauck MA, Zinman B, Daniels GH, Pocock S, Steinberg WM, Bergenstal RM, Mann JF, Ravn LS, Frandsen KB, Moses AC, Buse JB. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J 2013; 166: 823-830.e5 [PMID: 24176437 DOI: 10.1016/j.ahj.2013.07.012]
45. Zaccardi F, Htike ZZ, Webb DR, Khunti K, Davies MJ. Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments: A Systematic Review and Network Metaanalysis. Ann Intern Med 2016; 164: 102-113 [PMID: 26642233 DOI: 10.7326/M15-1432]